Javascript must be enabled to continue!
Abstract 4373096: Inpatient Outcomes After Heart Transplantation With and Without LVAD Bridging
View through CrossRef
Introduction:
Heart failure (HF) is one of the leading causes of hospitalization and mortality in the United States. Heart transplantation (HT) remains the definitive treatment for end-stage HF, sometimes preceded by left ventricular assist device (LVAD) implantation as a bridge to transplant. However, national data on inpatient outcomes for HT recipients with and without LVAD bridging remain limited.
Methods:
We analyzed the Nationwide Readmissions Database (NRD) from 2016–2019 to identify adult patients who underwent HT and were discharged between January and November of each year. Patients with missing data on event time or length of stay were excluded. Survey-weighted procedures were applied to account for the complex sampling design. We compared inpatient outcomes between patients who received LVAD implantation during the same index hospitalization and those who did not. Data were analyzed using SAS 9.4.
Results:
We identified 11,351 weighted adult patients who underwent HT from January to November 2016–2019. Of these, 2% (n=233) received LVAD during the same index hospitalization. LVAD recipients were younger (mean age: 50.7 vs. 53.3 years) and less likely to be female (23% vs. 27%) compared to non-LVAD patients. They also had higher rates of comorbidities, including acute encephalopathy (35% vs. 15%), advanced chronic kidney disease (19% vs. 9%), and cardiac cachexia (42% vs. 21%) (all p < 0.001). LVAD recipients required more intensive inpatient interventions, such as percutaneous coronary intervention (1.7% vs. 0.6%), coronary artery bypass grafting (3.4% vs. 0.2%), intra-aortic balloon pump (27% vs. 19%), extracorporeal membrane oxygenation (28% vs. 9%), and peripheral VAD (63% vs. 4%) (all p < 0.001). These patients experienced longer hospital stays (mean: 85 vs. 38 days) and higher inpatient mortality (15% vs. 5%, p < 0.0007), as well as greater 30-day readmission mortality (1.3% vs. 0.2%, p = 0.01). Multivariable analysis identified acute encephalopathy, coagulopathy, and cardiac cachexia as independent predictors of inpatient mortality after adjusting for age, sex, kidney disease, and LVAD bridging.
Conclusion:
Heart transplant recipients requiring LVAD implantation during the same hospitalization experience significantly worse inpatient outcomes, including higher mortality and resource utilization. Early identification and risk stratification of these patients may help guide perioperative management and improve outcomes.
Ovid Technologies (Wolters Kluwer Health)
Title: Abstract 4373096: Inpatient Outcomes After Heart Transplantation With and Without LVAD Bridging
Description:
Introduction:
Heart failure (HF) is one of the leading causes of hospitalization and mortality in the United States.
Heart transplantation (HT) remains the definitive treatment for end-stage HF, sometimes preceded by left ventricular assist device (LVAD) implantation as a bridge to transplant.
However, national data on inpatient outcomes for HT recipients with and without LVAD bridging remain limited.
Methods:
We analyzed the Nationwide Readmissions Database (NRD) from 2016–2019 to identify adult patients who underwent HT and were discharged between January and November of each year.
Patients with missing data on event time or length of stay were excluded.
Survey-weighted procedures were applied to account for the complex sampling design.
We compared inpatient outcomes between patients who received LVAD implantation during the same index hospitalization and those who did not.
Data were analyzed using SAS 9.
4.
Results:
We identified 11,351 weighted adult patients who underwent HT from January to November 2016–2019.
Of these, 2% (n=233) received LVAD during the same index hospitalization.
LVAD recipients were younger (mean age: 50.
7 vs.
53.
3 years) and less likely to be female (23% vs.
27%) compared to non-LVAD patients.
They also had higher rates of comorbidities, including acute encephalopathy (35% vs.
15%), advanced chronic kidney disease (19% vs.
9%), and cardiac cachexia (42% vs.
21%) (all p < 0.
001).
LVAD recipients required more intensive inpatient interventions, such as percutaneous coronary intervention (1.
7% vs.
0.
6%), coronary artery bypass grafting (3.
4% vs.
0.
2%), intra-aortic balloon pump (27% vs.
19%), extracorporeal membrane oxygenation (28% vs.
9%), and peripheral VAD (63% vs.
4%) (all p < 0.
001).
These patients experienced longer hospital stays (mean: 85 vs.
38 days) and higher inpatient mortality (15% vs.
5%, p < 0.
0007), as well as greater 30-day readmission mortality (1.
3% vs.
0.
2%, p = 0.
01).
Multivariable analysis identified acute encephalopathy, coagulopathy, and cardiac cachexia as independent predictors of inpatient mortality after adjusting for age, sex, kidney disease, and LVAD bridging.
Conclusion:
Heart transplant recipients requiring LVAD implantation during the same hospitalization experience significantly worse inpatient outcomes, including higher mortality and resource utilization.
Early identification and risk stratification of these patients may help guide perioperative management and improve outcomes.
Related Results
Abstract 14995: Outcomes of Transcatheter Aortic Valve Replacements in Patients With Left Ventricular Assist Device
Abstract 14995: Outcomes of Transcatheter Aortic Valve Replacements in Patients With Left Ventricular Assist Device
Background:
The development or progression of aortic insufficiency (AI) to moderate to severe in patients with left ventricular assist devices (LVADs) for end stage hea...
Impact on mortality of heart transplantation preceded or not by continuous-flow left ventricular assist devices
Impact on mortality of heart transplantation preceded or not by continuous-flow left ventricular assist devices
Abstract
Background
Heart transplant (HT) is the therapy of choice in end-stage heart failure patients. With the scarcity of don...
Abstract 4136813: Redox Serum Proteomics Of Left Ventricular Assist Device Unloaded Human Heart
Abstract 4136813: Redox Serum Proteomics Of Left Ventricular Assist Device Unloaded Human Heart
Heart failure (HF) is a global epidemic claiming millions of lives worldwide. Unloading the heart of end-stage HF patients via left ventricular assist devices (LVADs) is used not o...
P6325Gas exchange improvements during exercise correlate with hemodynamic changes in heart failure patients with a left ventricular assist device
P6325Gas exchange improvements during exercise correlate with hemodynamic changes in heart failure patients with a left ventricular assist device
Abstract
Background
The implantation of left ventricular assist devices (LVAD) has established its role in therapy for patients ...
Sexual Function in Patients Supported with Left Ventricular Assist Device and with Heart Transplant
Sexual Function in Patients Supported with Left Ventricular Assist Device and with Heart Transplant
Abstract
Aims
Sexual dysfunction is common among patients with heart failure (HF) and considered an important hamper to q...
1801. LVAD antimicrobial prophylaxis and infections, a 12-year experience
1801. LVAD antimicrobial prophylaxis and infections, a 12-year experience
Abstract
Background
The incidence of end-stage heart failure necessitating advanced cardiac therapy continues to increase in the...
Data-driven innovation of left ventricular assist device therapy
Data-driven innovation of left ventricular assist device therapy
Heart failure is a global and growing problem that affects 1-2% of people. For patients with end-stage heart failure, a heart transplant is the “gold standard”. Due to the permanen...
Outcomes of implantable cardioverter-defibrillators in patients with a left ventricular assist device: a systematic review and meta-analysis
Outcomes of implantable cardioverter-defibrillators in patients with a left ventricular assist device: a systematic review and meta-analysis
Abstract
Introduction
Implantable Cardioverter-Defibrillators (ICDs) improve survival in advanced heart failure with reduced eje...

